Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Insmed Incorporated

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ocular Therapeutix (OCUL – Research Report), Insmed ...

Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Insmed (INSM) and Orchestra BioMed Holdings (OBIO)

In a report released on December 5, Andrew Fein from H.C. Wainwright maintained a Buy rating on Insmed, with a price target of $240.00. The company...

Insmed (INSM) Receives a Rating Update from a Top Analyst

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Capricor Therapeutics (CAPR – Research Report) and I...

Analysts’ Top Healthcare Picks: Capricor Therapeutics (CAPR), Insmed (INSM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE – Research Report) and Insm...

Analysts Are Bullish on Top Healthcare Stocks: Spyre Therapeutics (SYRE), Insmed (INSM)

Jefferies analyst Kelly Shi maintained a Buy rating on Insmed today and set a price target of $230.00. According to TipRanks, Shi is a 4-star analy...

Jefferies Sticks to Their Buy Rating for Insmed (INSM)

Insmed ( ($INSM) ) has provided an announcement. On November 18, 2025, Insmed announced that the European Commission approved BRINSUPRI (brensocati...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INSM	$197.01	+0.91%	1.90M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INSM	$197.01	+0.9%	1.90M
3
4
5
6

INSM

INSM

Dividend Overview

Get Insmed Incorporated Data in Excel

Get Insmed Incorporated Data in Excel